Mitchell Ho, Ph.D.

Mitchell Ho, Ph.D.
Deputy Chief
Senior Investigator
Head, Antibody Therapy Section
Director, NCI CCR Antibody Engineering Program

Dr. Ho's laboratory studies molecular basis of cell surface receptors and generates antibodies to modulate them. A major focus of the work is on the structure and function of glypicans (GPC3 and GPC2) and establishing them as new cancer targets. This area of research ranges from investigation of the mechanisms by which glypicans regulate Wnt, Yap and other signaling pathways to the development of new antibody engineering technologies that lead to effective cancer therapeutics. In line with the antibody technology development, his lab constructs shark and camel single domain antibody libraries for phage display. The antibodies, immunotoxins and CAR T cells created in his lab are being tested at preclinical and clinical stages for liver cancer, neuroblastoma and mesothelioma. Dr. Ho is also Director of the NCI CCR Antibody Engineering Program.

Areas of Expertise

1) heparan sulfate proteoglycan, 2) Wnt and Yap signaling, 3) mesothelin, 4) immunotoxins, 5) CAR T cells, 6) protein and antibody engineering, 7) phage display, 8) mammalian cell display, 9) human and humanized monoclonal antibodies, 10) single domain antibodies

Contact Info

Mitchell Ho, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 37, Room 5002
Bethesda, MD 20892-4264
Ph: 240-760-7848
homi@mail.nih.gov

Dr. Ho's laboratory studies cell surface proteins in broad scientific fields of molecular and cellular biology including receptor/ligand interactions, signaling pathways, antibody/protein engineering, structure and computational biology, and functional genomics. We also develop new antibody technologies. Some of our research has direct clinical application.

Dissecting cell surface receptors in cancer: structure and function

Antibody-based therapy has shown promising efficacy in hematologic tumors. However, this approach has shown limitations in most solid cancers. One of the critical factors for treating solid tumors is the identification of cancer-specific targets. Our long-term research interests lie primarily in the biology of cell surface receptors including glypicans (GPC3 and GPC2) and mesothelin for establishing them as cancer targets.

Mesothelin is a target candidate in many solid tumors. To understand its biological function, we collaborated with Byungkook Lee (NCI) to make a structure model and experimentally identified the functional binding domain for MUC16/CA125 around Y318 (residues 296-359; named IAB) consisting of 64 amino acids at the N-terminus of cell surface mesothelin. Our work supports the role of mesothelin and MUC16/CA125 as functional partners in the tumor microenvironment and cancer development.

Heparan and chondroitin sulfate proteoglycans (HSPGs and CSPGs, respectively) are important modulators of signal transduction pathways during development and disease. HSPGs mainly consist of glycosylphosphatidylinositol (GPI)-anchored glypicans and transmembrane syndecans. Much of our work has focused on fundamental aspects of glypicans in connections to Wnt/Yap signaling and cancer cell growth. Our goal is to investigate glypicans as new targets in cancer.  

We identified the Wnt functional binding sites on GPC3, one in the protein core and the other in heparan sulfate chains. First, we built a structure model of the GPC3/Wnt complex in collaboration with Byungkook Lee, then experimentally validated our model to determine the Wnt functional binding site on GPC3, providing evidence for GPC3 as a co-receptor for regulating Wnt. To explore the role of GPC3 in other signaling pathways, we conducted the original research that revealed the role of GPC3 in regulating Yap for liver cancer cell proliferation and discovered another signaling interaction between GPC3 and HGF in liver cancer. Recently, we identified FAT1, a potential cell surface receptor of Yap signaling in mammalian cells, was a novel GPC3 interacting protein in liver cancer cells. Furthermore, we found that our Wnt blocking single domain antibody (HN3) was capable of reaching the previously undescribed Wnt functional binding site in the N-lobe of the protein core of GPC3 and that F41 was the key residue in the hydrophobic groove for Wnt and HN3 binding. Additionally, we used our HS20 human antibody specific for the heparan sulfate chains of GPC3 to determine the Wnt binding motif which may function as a Wnt storage/transporter site on heparan sulfate chains. In collaboration with Jian Liu (University of North Carolina), we found that Wnt recognized a heparan sulfate structure containing IdoA2S and GlcNS6S, and that the 3-O-sulfation in GlcNS6S3S could enhance the binding of Wnt.

We started to apply what we learned from our GPC3 project to explore other glypicans in cancer. We found that GPC2 protein was expressed in nearly half of neuroblastoma cases and that GPC2 knockout inactivated Wnt/β-catenin signaling and reduced the expression of the target gene, N-Myc, an oncogenic driver of neuroblastoma tumorigenesis. Furthermore, we conducted the proof-of-concept study that showed CAR T cells and immunotoxins targeting GPC2 could inhibit neuroblastoma growth in mouse models. As a result, we reported GPC2 to be a new therapeutic target in neuroblastoma.

Engineering antibody therapeutics for treating cancer: immunotoxins and CAR T cells

To overcome the limitations of antibody-based immunotherapy for solid tumors, we used multiple antibody technologies to generate large panels of human and xenogeneic antibodies and utilized multiple effector mechanisms to improve the anti-tumor activity of our tumor antigen-specific monoclonal antibodies. We have developed multiple strategies with different mechanisms of actions, such as immunotoxins, ADCs and CAR T cells. Our research program focuses on the development and implementation of antibody-based immunotherapeutic strategies for the treatment of solid tumors, including hepatocellular carcinoma (HCC), pancreatic cancer, neuroblastoma and mesothelioma. The strategies developed in our program may be applicable to other solid tumors.

We generated antibodies (HN3 and YP7) that bind glypican-3 (GPC3) on liver cancer cells. HN3 is a human single domain antibody isolated using phage display technology, which recognizes a cryptic Wnt binding site in the N-lobe of GPC3. YP7 is a monoclonal antibody isolated using mouse hybridoma technology, which binds an epitope at the C-lobe of GPC3 close to cell surface. Using these antibodies, we generated immunotoxins and ADCs to target GPC3-expressing cancers. We constructed a novel immunotoxin that can produce tumor regression via a dual mechanism of action. These immunotoxins inactivate cancer signaling via the antibody domain and inhibit protein synthesis via the toxin portion. This dual mechanism of action may be applicable to other antibody-toxin/drug conjugates for better anti-tumor efficacy. Immunogenicity and a short serum half-life may limit the ability of immunotoxins to transition to the clinic. To address these concerns, we engineered HN3-based immunotoxins in collaboration with Ira Pastan (NCI) to use various deimmunized Pseudomonas exotoxin (PE) domains and added an albumin binding single domain. We also designed CAR T cells using our GPC3 antibodies and demonstrated that humanized YP7 (hYP7) antibody derived CAR T cells had potent and persistent anti-tumor activity in orthotopic liver cancer mouse models. This was accomplished by using functional genomics sequencing and single cell-based T cell analysis.

Mesothelin is highly expressed in mesothelioma and various solid tumors. We previously isolated HN1, a human monoclonal antibody that disrupts the mesothelin-MUC16 interaction. Our recent research has been focused on the targeting of the membrane proximal region of mesothelin for enhanced anti-tumor activities. As a result, we isolated YP218, a unique rabbit monoclonal antibody targeting the C-terminal portion of mesothelin close to the tumor cell surface.

Developing antibody technology: single domain antibodies

We have developed a variety of antibody technologies to produce therapeutic antibodies. These include cell-based screening methodology for isolating antibodies using rabbit and mouse hybridomas, humanization of rabbit and mouse antibodies, and construction of phage display libraries for antibody discovery. Our antibody technologies, such as single domain antibody libraries, can be used to identify therapeutic and diagnostic antibodies for human diseases including cancer, infectious disease and neurological disease.

Single domain antibodies (also commonly called nanobodies) are known to bind restricted epitopes that may be inaccessible to conventional antibodies. To make a large single domain phage library, we established a method based on PCR-Extension Assembly and Self-Ligation (named ‘EASeL’) to construct a VNAR single domain antibody library from six nurse sharks (Ginglymostoma cirratum) in collaboration with Martin Flajnik (University of Maryland). We conducted next-generation sequencing analysis of 1.2 million shark VNAR single domains and showed that our shark single domain library is highly diverse. In addition, we applied the EASeL method to construct VHH single domain phage libraries from 20 camels (Camelus dromedaries). Single domain antibodies isolated from our phage libraries can have a high affinity (KD = 1 nM or less) for their tumor or viral antigens.

Antibody engineering is typically carried out by displaying antibody fragments on the surface of microorganisms (e.g. phage, bacteria and yeast). We established a new antibody engineering method known as 'mammalian cell display' that is adapted from yeast cell display. Using this approach, antibody fragments are expressed on human HEK-293 cells, and high affinity antigen binders are isolated from a combinatory library via flow cytometry.

Drug resistance is an important component of tumor biology that requires a complex cellular environment for study. We have established ex vivo tumor spheroid models using cell lines and primary patient cells in collaboration with Shuichi Takayama (University of Michigan) and V. Courtney Broaddus (UCSF). This allows us to study the molecular mechanisms of antibody drug resistance in a physiologically relevant cellular model. We have also used microarrays to profile gene expression in both spheroids and monolayers to identify new targets specific to the 3D biological structure of cancer.

Teaching Interests:

BIOC301/302 - Biochemistry I/II

NIH Scientific Focus Areas:
Biomedical Engineering and Biophysics, Cancer Biology, Cell Biology, Immunology, Molecular Biology and Biochemistry
  1. Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropublic B, Hewitt SM, Orentas RJ, Greten TF, Ho M.
    Gastroenterology. doi: 10.1053/j: 2020. [ Journal Article ]
  2. Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y, Feng M, Lee B, Gao W, Ho M.
    Hepatology. 10.1002/hep.30646: 2019. [ Journal Article ]
  3. Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M.
    Proc Natl Acad Sci U S A.. doi: 10.1073/pnas.1706055114., 2017. [ Journal Article ]
  4. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M
    Nat. Commun.. 6: 6536, 2015. [ Journal Article ]
  5. Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
    Proc Natl Acad Sci U S A.. 110 (12): E1083-91, 2013. [ Journal Article ]

Mitchell Ho received a B.S. from East China Normal University and a M.A. from San Francisco State University. After briefly working at DNAX Research Institute and Protein Design Labs as a research associate, he moved to the University of Illinois at Urbana-Champaign, where he received his Ph.D. as a National Research Service Award Predoctoral Fellow. He completed a postdoctoral fellowship with Ira Pastan at the NIH/NCI. Dr. Ho was recruited in 2008 as a Tenure Track Investigator at the NCI and promoted to a tenured Senior Investigator in 2015.

Dr. Ho is currently Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the NCI. He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief for Antibody Therapeutics (Oxford University Press). He was elected to the Board of Directors for the Antibody Society and received Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award (2017), NIH Deputy Director for Intramural Research (DDIR) Innovation Award (2017), NIH Merit Award (2014), NCI Director's Award (2017) and NCI Director’s Innovation Award (2011).

Position Degree Required Contact Name E-mail Address
Post-doctoral Fellow - CAR T cell therapy, T cell immunology Ph.D. or equivalent, M.D. or equivalent Dr. Mitchell Ho homi@mail.nih.gov
Name Position
Jesse Buffington B.S. Postbaccalaureate Fellow (CRTA)
Zhijian Duan Ph.D. Postdoctoral Fellow (Visiting)
Ashley Gallagher MRSP Fellow
Jessica Hong Research Biologist
Aarti Kolluri Predoctoral Fellow (Graduate Student)
Dan Li Ph.D. Postdoctoral Fellow (Visiting)
Nan Li Ph.D. Staff Scientist
Tianyuzhou Liang Postbaccalaureate Fellow (CRTA)
Shaoli Lin Ph.D. Postdoctoral Fellow (Visiting)
Madeline Spetz Postbaccalaureate Fellow (CRTA)

Nanobodies inhibiting SARS-CoV-2 binding to ACE (NIH/FDA COVID-19 Research Workshop, 10/2020)

Received Intramural Targeted Anti-COVID-19 (ITAC) Awards for the project "Development of Neutralizing Nanobodies Against SARS-CoV-2" (NIH OIR, 09/29/2020)

Serendipitous Collaboration Leads to Potential Therapy for Liver Cancer (NCIatFrederick Poster, 08/17/2020)

Pandemic Brings All Hands on Deck  (NIH IRP Intramural Blog, 06/16/2020)

New therapies tested in mice provide a one-two punch for treating liver cancer (NCI CCR News , 11/01/2018)

A protein in neuroblastoma could be a target of immunotoxins or immunotherapy (NCI CCR News, 07/01/2017)